Given that CXCL10 expression by tumors is associated with effective anti-tumor immunity and CD8+ T-cell regulation [46], we did not expect to observe a negative correlation between circulating levels of CXCL10 and PFS in patients with stage I NSCLC treated with SBRT. The gene discussed is CXCL10; the disease is neoplasm.